Hurdles to breakthrough in CAR T cell therapy of solid tumors.
CAR-T cell
Chimeric antigen receptor
Solid tumors
Tumor microenvironment
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
09
08
2021
accepted:
13
01
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Autologous T cells genetically engineered to express chimeric antigen receptor (CAR) have shown promising outcomes and emerged as a new curative option for hematological malignancy, especially malignant neoplasm of B cells. Notably, when T cells are transduced with CAR constructs, composed of the antigen recognition domain of monoclonal antibodies, they retain their cytotoxic properties in a major histocompatibility complex (MHC)-independent manner. Despite its beneficial effect, the current CAR T cell therapy approach faces myriad challenges in solid tumors, including immunosuppressive tumor microenvironment (TME), tumor antigen heterogeneity, stromal impediment, and tumor accessibility, as well as tribulations such as on-target/off-tumor toxicity and cytokine release syndrome (CRS). Herein, we highlight the complications that hamper the effectiveness of CAR T cells in solid tumors and the strategies that have been recommended to overcome these hurdles and improve infused T cell performance.
Identifiants
pubmed: 35365241
doi: 10.1186/s13287-022-02819-x
pii: 10.1186/s13287-022-02819-x
pmc: PMC8974159
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
© 2022. The Author(s).
Références
Immunogenetics. 2012 Feb;64(2):77-85
pubmed: 22146829
Mol Ther. 2016 Jun;24(6):1135-1149
pubmed: 27019998
J Leukoc Biol. 2010 Feb;87(2):265-73
pubmed: 19892848
J Clin Invest. 2017 Mar 1;127(3):929-941
pubmed: 28165340
Acta Pharmacol Sin. 2015 Oct;36(10):1219-27
pubmed: 26388155
Small. 2021 Oct;17(43):e2102624
pubmed: 34378338
Cancer Gene Ther. 2021 Jun 22;:
pubmed: 34158626
Immunity. 2014 Oct 16;41(4):518-28
pubmed: 25367569
J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Oncoimmunology. 2017 Feb 6;6(3):e1284722
pubmed: 28405515
Neuro Oncol. 2019 Nov 4;21(11):1436-1446
pubmed: 31276594
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Cancer Immunol Res. 2016 Aug;4(8):658-68
pubmed: 27329987
Clin Cancer Res. 2011 Jul 1;17(13):4296-308
pubmed: 21478334
Front Immunol. 2018 Oct 29;9:2493
pubmed: 30420856
Mol Ther Nucleic Acids. 2013 Jul 09;2:e105
pubmed: 23839099
Oncotarget. 2016 Jun 7;7(23):34341-55
pubmed: 27145284
Immunotherapy. 2012 Nov;4(11):1129-38
pubmed: 23194363
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Mol Ther. 2013 Nov;21(11):2087-101
pubmed: 23939024
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32990678
Cancer Immunol Res. 2013 Jul;1(1):43-53
pubmed: 24409448
PLoS One. 2014 Oct 15;9(10):e109992
pubmed: 25333973
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Cancer Immunol Res. 2017 Nov;5(11):950-956
pubmed: 28963140
Emerg Top Life Sci. 2017 Dec 12;1(5):447-456
pubmed: 33525802
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Front Cell Dev Biol. 2019 Jul 05;7:86
pubmed: 31334229
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
J Immunother. 2020 Jan;43(1):16-28
pubmed: 31574023
Cancer Immunol Res. 2015 May;3(5):506-17
pubmed: 25672397
Cancer Immunol Res. 2019 Mar;7(3):363-375
pubmed: 30651290
Pathol Res Pract. 2020 Nov;216(11):153229
pubmed: 33010699
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
J Clin Invest. 2017 Jun 30;127(7):2473-2481
pubmed: 28628037
Mol Ther Methods Clin Dev. 2020 Dec 25;20:379-388
pubmed: 33575430
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
J Immunol. 2012 Jun 15;188(12):6389-98
pubmed: 22586039
Curr Opin Immunol. 2015 Apr;33:55-63
pubmed: 25665467
Mol Ther. 2019 Aug 7;27(8):1483-1494
pubmed: 31078430
Oncotarget. 2017 Mar 7;8(10):17002-17011
pubmed: 28199983
Clin Transl Immunology. 2019 May 11;8(5):e1049
pubmed: 31110702
Cancer Res. 2013 Jun 1;73(11):3371-80
pubmed: 23633494
Cancer Immunol Res. 2014 Feb;2(2):154-66
pubmed: 24778279
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
Mol Ther. 2017 Jan 4;25(1):249-258
pubmed: 28129119
Cancer Res. 2017 Mar 15;77(6):1296-1309
pubmed: 28082401
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Theranostics. 2020 Jun 18;10(17):7622-7634
pubmed: 32685008
Cancer Cell. 2017 Nov 13;32(5):669-683.e5
pubmed: 29136509
Mol Cancer Ther. 2012 May;11(5):1062-70
pubmed: 22532596
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Mol Ther Oncolytics. 2016 Dec 14;4:41-54
pubmed: 28345023
Blood. 2006 Aug 1;108(3):804-11
pubmed: 16861339
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Mol Ther Oncolytics. 2020 Jun 24;18:226-235
pubmed: 32728611
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
Acta Pharm Sin B. 2018 Jul;8(4):539-551
pubmed: 30109179
J Biol Chem. 2019 Apr 5;294(14):5430-5437
pubmed: 30804212
Mol Ther. 2021 Jul 7;29(7):2335-2349
pubmed: 33647456
EBioMedicine. 2019 Sep;47:235-246
pubmed: 31462392
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Cancer Res. 2016 Mar 15;76(6):1578-90
pubmed: 26979791
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123068
Cell Rep Med. 2021 Apr 09;2(4):100227
pubmed: 33948568
Brief Funct Genomics. 2020 May 20;19(3):175-182
pubmed: 31950135
Cancer Immunol Res. 2016 Oct;4(10):869-880
pubmed: 27549124
Mol Ther. 2015 Apr;23(4):769-78
pubmed: 25582824
Br J Haematol. 2008 Mar;140(5):527-36
pubmed: 18275430
Oncoimmunology. 2019 Jun 7;8(9):e1621676
pubmed: 31428518
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Cancer Immunol Immunother. 2015 Jul;64(7):817-29
pubmed: 25850344
Hum Gene Ther. 2019 Apr;30(4):446-458
pubmed: 29706119
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Oncoimmunology. 2015 Jan 23;4(3):e994446
pubmed: 25949921
Mol Ther. 2021 Feb 3;29(2):702-717
pubmed: 33129371
Mol Ther. 2013 Aug;21(8):1611-20
pubmed: 23732988
J Immunother Cancer. 2017 Mar 21;5:28
pubmed: 28331617
Front Med. 2017 Dec;11(4):554-562
pubmed: 28625015
Cancer Res. 2015 Sep 15;75(18):3853-64
pubmed: 26183927
Immunity. 2016 Feb 16;44(2):380-90
pubmed: 26885860
Microorganisms. 2020 Nov 10;8(11):
pubmed: 33182527
Cell Rep. 2017 Dec 12;21(11):3205-3219
pubmed: 29241547
Nat Med. 2015 May;21(5):524-9
pubmed: 25849134
Front Oncol. 2018 Oct 17;8:453
pubmed: 30386740
Clin Cancer Res. 2011 Jul 15;17(14):4719-30
pubmed: 21610146
Clin Cancer Res. 2010 Nov 15;16(22):5458-68
pubmed: 20889916
Cancer Res. 2014 Sep 15;74(18):5195-205
pubmed: 25060519
Mol Ther. 2019 Jun 5;27(6):1126-1138
pubmed: 31005597
Oncoimmunology. 2021 Mar 18;10(1):1899469
pubmed: 33796409
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Science. 2015 Oct 16;350(6258):aab4077
pubmed: 26405231
Cells. 2020 Apr 16;9(4):
pubmed: 32316275
Front Immunol. 2021 Mar 03;12:640082
pubmed: 33746981
Gene Ther. 2013 Oct;20(10):970-8
pubmed: 23636245
Leukemia. 2006 Oct;20(10):1819-28
pubmed: 16932339
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Mol Immunol. 2012 Jul;51(3-4):263-72
pubmed: 22503210
J Vis Exp. 2019 Jul 22;(149):
pubmed: 31380838
Cancer Immunol Res. 2016 Jun;4(6):541-51
pubmed: 27045023
Mol Ther. 2017 Aug 2;25(8):1946-1958
pubmed: 28506593
J Immunother Cancer. 2019 Mar 12;7(1):68
pubmed: 30867051
Cell. 2016 Feb 11;164(4):770-9
pubmed: 26830879
Clin Cancer Res. 2019 Jan 1;25(1):358-368
pubmed: 30425092
J Transl Med. 2013 Aug 12;11:187
pubmed: 23937772
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Blood. 2012 May 3;119(18):4133-41
pubmed: 22354001
Cancer Res. 2007 Mar 1;67(5):2265-73
pubmed: 17332357
J Clin Invest. 2016 Aug 1;126(8):3130-44
pubmed: 27454297
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
JCI Insight. 2020 Feb 27;5(4):
pubmed: 31999649
J Clin Invest. 2010 Nov;120(11):3953-68
pubmed: 20978347
Nat Methods. 2019 Mar;16(3):247-254
pubmed: 30804551
Immunol Res. 2020 Feb;68(1):63-70
pubmed: 32096010
Cancer Res. 2018 Aug 15;78(16):4692-4703
pubmed: 29967261
Oncoimmunology. 2016 Dec 23;6(2):e1273302
pubmed: 28344886
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997304
Sci Rep. 2016 Jan 11;6:18950
pubmed: 26750734
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
J Hematol Oncol. 2020 Jul 20;13(1):99
pubmed: 32690037
Cancer Immunol Res. 2015 Jan;3(1):68-84
pubmed: 25358763
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
J Immunother. 2010 Oct;33(8):780-8
pubmed: 20842059
Am J Pathol. 2000 Feb;156(2):529-36
pubmed: 10666382
J Immunol. 2007 May 1;178(9):5552-62
pubmed: 17442937
Front Oncol. 2019 Apr 17;9:241
pubmed: 31058074
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
Nat Immunol. 2013 Nov;14(11):1173-82
pubmed: 24076634
Oncoimmunology. 2019 Nov 4;9(1):1684127
pubmed: 32002297
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Front Immunol. 2020 Jun 17;11:1109
pubmed: 32625204
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
Sci Rep. 2017 Jan 20;7:39833
pubmed: 28106050
Mol Ther. 2014 Mar;22(3):623-633
pubmed: 24213558
Am J Pathol. 2011 Mar;178(3):1221-32
pubmed: 21356373
BMC Cancer. 2019 Jun 25;19(1):628
pubmed: 31238897
Cancer Immunol Res. 2021 Jun;9(6):707-722
pubmed: 33875483
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Sci Rep. 2017 Sep 5;7(1):10541
pubmed: 28874817
Clin Cancer Res. 2015 Jul 15;21(14):3113-20
pubmed: 25908780
Cancer Res. 2011 Apr 15;71(8):2871-81
pubmed: 21487038
J Immunol. 2019 Oct 1;203(7):1999-2010
pubmed: 31471524
Front Immunol. 2012 Sep 05;3:268
pubmed: 22973270
Front Oncol. 2019 Apr 30;9:322
pubmed: 31114756
J Hematol Oncol. 2018 Nov 27;11(1):132
pubmed: 30482221
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Front Immunol. 2021 Oct 06;12:744823
pubmed: 34691052
Biochim Biophys Acta. 2011 May;1808(5):1400-12
pubmed: 20888788
Front Cell Dev Biol. 2020 Aug 18;8:803
pubmed: 32974346
Blood. 2015 Jun 18;125(25):3905-16
pubmed: 25940712
J Hematol Oncol. 2019 Jun 20;12(1):62
pubmed: 31221182
Cancer Res. 2014 Feb 1;74(3):665-74
pubmed: 24336068
Mol Ther Oncolytics. 2020 Apr 29;17:408-420
pubmed: 32462078
J Immunother Cancer. 2017 May 16;5:42
pubmed: 28515942
Immunol Res. 2013 Mar;55(1-3):58-70
pubmed: 22961658
Cancer Res. 2019 Aug 15;79(16):4149-4159
pubmed: 31248966
Clin Cancer Res. 2008 Oct 1;14(19):5947-52
pubmed: 18829471
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Cell Immunol. 2020 Feb;348:104041
pubmed: 31983398
Mol Ther. 2017 Sep 6;25(9):2214-2224
pubmed: 28602436
Leukemia. 2018 Sep;32(9):1970-1983
pubmed: 29483708
Blood. 2009 Jun 18;113(25):6392-402
pubmed: 19377047
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Mol Ther Nucleic Acids. 2017 Dec 15;9:312-321
pubmed: 29246309
Mol Pharm. 2018 Jun 4;15(6):2069-2083
pubmed: 29767984
Cancer Res. 2011 Sep 1;71(17):5697-706
pubmed: 21742772
Front Oncol. 2021 May 25;11:664421
pubmed: 34113569
Cell Rep. 2017 Sep 26;20(13):3025-3033
pubmed: 28954221
J Clin Oncol. 2006 May 1;24(13):e20-2
pubmed: 16648493
Cancer Res. 2015 Sep 1;75(17):3596-607
pubmed: 26330166
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573
Oncoimmunology. 2013 Oct 1;2(10):e26286
pubmed: 24353912
Cancer Res. 1996 Mar 1;56(5):1111-17
pubmed: 8640769
J Hematol Oncol. 2017 Jan 31;10(1):35
pubmed: 28143567
Oncoimmunology. 2021 Mar 31;10(1):1901434
pubmed: 33854821
Eur Radiol. 2017 Sep;27(9):3991-4001
pubmed: 28289945
Front Pharmacol. 2021 Mar 12;12:619800
pubmed: 33776765
Front Oncol. 2020 Apr 24;10:494
pubmed: 32391260
Cancer Cell. 2019 Nov 11;36(5):471-482
pubmed: 31715131
J Clin Invest. 2020 Mar 2;130(3):1405-1416
pubmed: 32015231
Cancer Immunol Res. 2014 Feb;2(2):112-20
pubmed: 24579088
J Immunother Cancer. 2019 Nov 14;7(1):304
pubmed: 31727131
Mol Ther. 2011 Apr;19(4):760-7
pubmed: 21326215
Cancer Discov. 2017 Oct;7(10):1154-1167
pubmed: 28576927
Nat Commun. 2019 Nov 13;10(1):5100
pubmed: 31723132
J Transl Med. 2015 Mar 28;13:102
pubmed: 25890361
Mol Ther. 2021 Jan 6;29(1):75-85
pubmed: 32956627
Front Immunol. 2018 Jul 19;9:1650
pubmed: 30072995